We thus propose a novel hypothesis: PLS3 may drive HNSCC progression by synergistically activating EMT and remodeling an immunosuppressive TIME, thereby establishing a bidirectional “pro-metastatic–immune evasive” axis. Here, PLS3 is linked to head and neck squamous cell carcinoma.